Tumor Vaccination Using Foreign Antigen Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic tumor vaccines rely on tumor antigens, which are evasive and patient-specific, making them ineffective for broad application and challenging to stabilize over time, as they fail to actively manipulate the antigenic state of the tumor.
Innovation Solution
A novel tumor-antigen independent vaccination strategy using a foreign, immunogenic antigen to stimulate an immune response, which is administered separately from the tumor site and later marked at the tumor site to activate an immune response against the tumor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tumor antigen-based vaccination is used, then T-cell activation against tumor-specific epitopes is achieved, but the vaccine effectiveness is reduced due to tumor immune evasion and patient-specific variability
Solution Approach 1:
The vaccine composition is segmented into two distinct components: (1) a tumor antigen component that provides tumor-specific targeting, and (2) a non-tumor antigen component that provides broad immune stimulation. This segmentation allows each component to fulfill its specific function while overcoming the limitations of using tumor antigens alone.
Solution Approach 2:
The non-tumor antigen acts as an intermediary that bridges the gap between the immune system and the tumor. It provides a reliable immunogenic signal that stimulates robust T-cell and antibody responses, which then transfer their activity to the tumor antigen component, enabling effective anti-tumor immunity without relying solely on variable tumor antigen expression.
2Reliability
If tumor-specific antigens are used, then patient-specific immune response is generated, but the antigen stability over time is poor due to tumor antigen alteration
Solution Approach 1:
The non-tumor antigen component provides preliminary and stable immune stimulation that occurs independently of tumor antigen changes. This preliminary immune activation creates a robust immune environment that can then recognize and respond to tumor antigens even as they change over time, effectively decoupling immune response stability from tumor antigen stability.
3Productivity
If recall antigens from prior vaccinations are used, then pre-existing memory T-cells and B-cells are re-activated providing strong immune response, but the response may not be sufficiently directed against the tumor
Solution Approach 1:
The vaccine merges two antigen types into a single composition: a non-tumor recall antigen that rapidly re-activates pre-existing memory immune cells, and a tumor antigen that provides tumor-specific targeting. The synergistic interaction between these components ensures both rapid immune response activation and accurate tumor targeting.
Solution Approach 2:
The non-tumor recall antigen component copies the successful strategy of conventional vaccines that use well-characterized, stable antigens to elicit strong immune responses. By incorporating this approach into the therapeutic vaccine framework, the invention leverages proven immunogenicity while directing the response toward tumor antigens through the combined composition.
Data Source
AI summary
A method for treating a tumor or generating an immune response against a tumor in a subject in need including a vaccination step comprising administration of a first composition, and a tumor-marking step comprising administration of a second composition, is provided. The first and second composition each comprises an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide. Also provided are antigenic polypeptides and compositions for use in methods described herein.